Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Terminated 4Active not recruiting 2

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 2Gastrointestinal 1Dermatologic 1

Conditions

Prostatic Neoplasms 2Uveal Melanoma 1Adenocarcinoma Of Esophagus 1

Interventions

Cyclophosphamide 391Carboplatin 344Gemcitabine 332pembrolizumab 331Cisplatin 328Paclitaxel 298Radiotherapy 297Docetaxel 287Bevacizumab 253Rituximab 234Capecitabine 224Nivolumab 222Dexamethasone 206Fluorouracil 190fludarabine 178Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 134Cetuximab 130fludarabine phosphate 129Bortezomib 129Lenalidomide 126Filgrastim 120Erlotinib Hydrochloride 120Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × benzamide × Clear all
NCT02555189 2026-04-22

Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

Thomas Jefferson University

Phase 1/2 Terminated
52 enrolled 31 charts
Genitourinary

Prostatic Neoplasms

NCT04720417 2025-07-15

Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma

Thomas Jefferson University

Phase 2 Terminated
13 enrolled 13 charts
Dermatologic

Uveal Melanoma

NCT03999515 2023-09-28

Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer

University of Washington

Phase 2 Terminated
3 enrolled 9 charts
Genitourinary

Prostatic Neoplasms

NCT02530437 2023-07-10

Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer

M.D. Anderson Cancer Center

Phase 1/2 Terminated
7 enrolled 11 charts
Gastrointestinal

Adenocarcinoma Of Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡